← All stories
Health, Longevity & Biohacking

Creator of NMR lipid testing warns LabCorp’s Vanta analysers may soon fail

Peter Attia Drive · 402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample · August 3, 2026
Creator of NMR lipid testing warns LabCorp’s Vanta analysers may soon fail
Peter Attia Drive
Peter Attia Drive
402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample
""what people don't know is that at some point in the future, maybe sooner rather than later, these Vanta analyzers, first generation, only generation, [laughter] uh, are going to cease to function.""
Jim Otvos, founder of Liposcience and developer of NMR-based lipoprotein testing, says the Vanta NMR analysers used for LabCorp’s NMR LipoProfile are ageing and could stop working. He argues the field needs an in‑vitro diagnostics (IVD) company to take on the technology so NMR-based assays can continue and scale beyond LabCorp’s current footprint.
From this episode
Peter Attia Drive
Peter Attia Drive

402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample

August 3, 2026 · 2h 27m · 7 Egleze moments
Read episode summary and key points →

More moments from this episode

Health, Longevity & BiohackingOtvos says MVX mortality-risk score is ‘virtually unassociated’ with ageHealth, Longevity & BiohackingNMR ‘glyc’ inflammation marker described as more stable than CRPHealth, Longevity & BiohackingOtvos says ‘fluffy’ LDL does not offset risk when LDL particle count is highAI & TechOtvos says NMR plus machine learning can output ApoB and lipid panel cheaply
More stories More from Peter Attia Drive